Show simple item record

dc.contributor.authorMoghaddas, A
dc.contributor.authorDianatkhah, M
dc.contributor.authorGhaffari, S
dc.contributor.authorGhaeli, P
dc.date.accessioned2018-08-26T09:41:04Z
dc.date.available2018-08-26T09:41:04Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58448
dc.description.abstractObjective: Management of borderline personality disorder (BPD) is a difficult challenge due to the complex features of this disorder. This article reviews the use of naltrexone in the treatment of BPD. Methods: Published articles and clinical trials were searched in Google Scholar, MedLine, ELSEVIER, and Cochrane database of systematic reviews abstracts in English language between 1990 and 2017. Results: Naltrexone (NTX), a nonspecific competitive opiate antagonist, has been noted to be helpful in controlling self-injurious behavior (SIB) and dissociative symptoms in patients with BPD. Conclusions: Further studies should be conducted on the effects of naltrexone to confirm the role of this medication in the treatment of BPD.
dc.language.isoEnglish
dc.relation.ispartofIranian Journal of Psychiatry
dc.subjectnaltrexone
dc.subjectopiate antagonist
dc.subjectopiate receptor
dc.subjectArticle
dc.subjectautomutilation
dc.subjectborderline state
dc.subjectCochrane Library
dc.subjectdata base
dc.subjectdecision making
dc.subjectdissociation
dc.subjectemotion
dc.subjecthuman
dc.subjectMedline
dc.subjectneuroendocrine system
dc.subjectpsychiatry
dc.titleThe potential role of naltrexone in borderline personality disorder
dc.typeArticle
dc.citation.volume12
dc.citation.issue2
dc.citation.spage141
dc.citation.epage146
dc.citation.indexScopus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record